<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref48">
 <label>48</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>La Torre</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>de Waure</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Chiaradia</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Mannocci</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Specchia</surname>
    <given-names>ML</given-names>
   </name>
   <name>
    <surname>Nicolotti</surname>
    <given-names>N</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>The future of best investing in vaccines: the Health Technology Assessment approach</article-title>
  <source>Vaccine</source>
  <year>2008</year>
  <volume>26</volume>
  <issue>13</issue>
  <fpage>1609</fpage>
  <lpage>1610</lpage>
  <pub-id pub-id-type="pmid">18289744</pub-id>
 </element-citation>
</ref>
